Pall Corporation (East Hills, NY) has purchased GeneSystems (Bruz, France), a privately held biotechnology company that has developed a molecular diagnostics platform.
Pall Corporation (East Hills, NY) has purchased GeneSystems (Bruz, France), a privately held biotechnology company that has developed a molecular diagnostics platform.
The acquisition of GeneSystems, with its patented approach to rapid microbiological detection equipment and disposables, expands Pall’s Total Fluid Management (TFM) capabilities in the $1-billion biopharmaceuticals process monitoring market.
Process monitoring includes the analytical tests required during biopharmaceuticals manufacturing for environmental monitoring, in-process control testing, and finished product release testing. These tests are receiving increased regulatory scrutiny and support under initiatives such as process analytical technology (PAT).
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.